SecBot SecBot
6-K ·Filed Nov 16, 2026

ENLV

Enlivex Ltd.
BEARISH
Impact 5/10
Horizonweeks Processed1d 8h ago SEC0001213900-26-120146
Notable filing: 6-K
Actionable Insight ▼ Bearish

Monitor the initial closing on November 17, 2026, and subsequent monthly closings for any delays or failures to fund. The need for shareholder approval to increase authorized share capital is a key risk that could postpone later tranches. The massive dilution relative to the current market cap (3.75x) will likely pressure the stock price. Watch for any clinical or regulatory catalysts that could alter the company's cash needs or investor sentiment.

DirectionBearish
Confidencehigh
Horizonweeks

Allocetra

◆ Mixed Named in this 6-K
Impact
Phase
Phase 2b
Time to market
At least 3-5 years if Phase 2b and subsequent Phase 3 trials succeed
Next catalyst
None dated

What to watchAllocetra's Phase 2a data in knee OA is intriguing (72% pain reduction in elderly patients), but the Phase 2b trial is only now starting enrollment with topline data not expected until mid-2027. Separately, ENLV's stock is heavily influenced by its RAIN token treasury (~$1.14B in tokens vs ~$127M market cap), this crypto overlay makes the stock more a prediction-markets proxy than a pure biotech play. Watch for Phase 2b enrollment updates and RAIN token price volatility.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Enlivex entered into a securities purchase agreement for a $7.5 million registered direct offering of ordinary shares (or pre-funded warrants) and accompanying ordinary warrants, priced at $1.315 per share unit (a 10.5% premium to the prior closing price). The offering will close in monthly tranches starting with $500,000 and continuing with $700,000 per month over 10 months, subject to shareholder approval for an increase in authorized share capital. The proceeds are intended for clinical, regulatory, manufacturing, R&D activities, potential acquisitions, and general corporate purposes.

Key Facts

  • Aggregate gross proceeds of approximately $7.5 million from the registered direct offering, assuming all closings are consummated.
  • Initial closing of $500,000 expected on or about November 17, 2026, with 10 subsequent monthly closings of $700,000 each from December 2026 through September 2027.
  • Combined purchase price of $1.315 per ordinary share (or $1.314 per pre-funded warrant) and accompanying ordinary warrant, representing a 10.5% premium to the November 13, 2026 closing price.
  • Ordinary warrants have an exercise price of $1.578 per share, exercisable immediately, expiring three years from initial closing.
  • Pre-funded warrants have an exercise price of $0.001 per share, exercisable immediately, no expiration.
  • If all ordinary warrants are exercised for cash, additional gross proceeds of approximately $9.0 million would be received.
  • Certain subsequent closings may be postponed until shareholder approval of an increase in authorized share capital is obtained.
  • Company market capitalization is approximately $2 million, making the $7.5 million offering size approximately 3.75x the current market cap.
  • Investors that meet a minimum subscription threshold may receive 5% of certain future payments from licensing or asset sales over a 24-month period.
  • The offering is being made directly by the company without a placement agent, underwriter, broker, or dealer.

Financial Impact

The offering size of $7.5 million is approximately 3.75 times the company's $2 million market capitalization, representing massive potential dilution. If all ordinary warrants are exercised for cash, an additional $9.0 million could be raised, bringing total potential proceeds to $16.5 million.

dilutionshare countcash balance

Risk Factors

  • Massive dilution: the $7.5 million offering is 3.75x the current $2 million market cap, which will significantly increase the share count and dilute existing holders.
  • Execution risk: subsequent closings are subject to shareholder approval for an increase in authorized share capital, which may not be obtained on a timely basis or at all.
  • Investor funding risk: there is a risk that one or more investors fail to fund their commitments at subsequent closings.
  • Warrant exercise risk: the ordinary warrants may not be exercised, limiting additional potential proceeds.
  • The company's market cap is extremely small ($2 million), making the stock highly volatile and sensitive to any news or funding developments.
  • The company operates a prediction markets treasury strategy involving digital assets (RAIN token), which introduces additional volatility and regulatory uncertainty.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-120146
Document: ea031165001ex99-1.htm0001213900-26-120146
Document: 0001213900-26-120146-index-headers.html0001213900-26-120146
Document: 0001213900-26-120146-index.html0001213900-26-120146
Document: 0001213900-26-120146.txt0001213900-26-120146
Earnings Context (Synthetic; results releases only)0001213900-26-120146

Track record

28 reports on ENLV

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +90.97% at T+60 after the Jul 28, 2026 report. 11 of 13 went positive at some point.

Filters
  1. Nov 17, 2026today 6-K Bearish 5/10 Entry price pending
  2. Nov 17, 2026today 6-K Bearish 5/10 Entry price pending
  3. Nov 17, 2026today 424B5 Bearish 5/10 Entry price pending
  4. Nov 16, 20261d ago 6-K Bearish 5/10 Viewing Entry $1.06 Now $1.15 −8.49% settles Nov 23
  5. Nov 2, 202615d ago 6-K Bullish 5/10 Entry $1.41 to $1.37 Now $1.15 −18.44% ▼ −2.84% −2.92% vs SPY
  6. Oct 28, 202620d ago 6-K Neutral 4/10 Entry $2.61 to $1.39 Now $1.15 −55.94% ▼ −46.74% −46.03% vs SPY
  7. Oct 27, 202621d ago 6-K Bearish 6/10 Entry $2.70 to $1.46 Now $1.15 +57.41% ▲ +45.93% +43.94% vs SPY
  8. Oct 22, 202626d ago 6-K Neutral 3/10 Entry $0.1734 to $0.1113 Now $1.15 +563.21% ▼ −35.84% −35.28% vs SPY
  9. Oct 22, 202626d ago Press Release Neutral 3/10 Entry $0.1734 to $0.1113 Now $1.15 +563.21% ▼ −35.84% −35.28% vs SPY
  10. Oct 19, 202629d ago 6-K Bearish 6/10 Entry $0.2070 to $0.1704 Now $1.15 −455.56% ▲ +17.68% +17.54% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens Wed (16h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026